C4 Therapeutics(US:CCCC) ZACKS·2025-11-06 14:26Core Insights - C4 Therapeutics, Inc. reported a quarterly loss of $0.44 per share, which was better than the Zacks Consensus Estimate of a loss of $0.47, representing an earnings surprise of +6.38% [1] - The company generated revenues of $11.23 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 72.77%, although this was a decline from $15.36 million in the same quarter last year [2] - C4 Therapeutics shares have underperformed, losing approximately 34.2% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $9.5 million, and for the current fiscal year, it is -$1.46 on revenues of $29.7 million [7] - The estimate revisions trend for C4 Therapeutics was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which C4 Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]